JP2011144111A - Axial myopia-preventing or treating agent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a therapeutic agent excellent in effects for preventing and treating axial myopia. <P>SOLUTION: The axial myopia-preventing or treating agent is characterized by containing a vasodilator action-having compound as an active ingredient. Concretely, bradykinin is exemplified, and is used by eye-dropping, intravitreous administration or oral administration. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to an agent for preventing or treating axial myopia.

  Myopia refers to a state in which light that has passed through the cornea does not form an image on the retina and cannot be clearly captured because it forms an image in front of the retina. As for myopia correction, there are more options for coping with the progress of spectacles, various contact lenses, and refractive surgery, but myopia is mainly binocular, progressing irreversibly, and socially active age. Due to the characteristic that the layer is affected, myopia itself leads to a decrease in QOL. On the other hand, medically, the risk of retinal detachment associated with intense myopia, myopic choroidal atrophy, myopic choroidal neovascularization, glaucoma, and cataract increases, and there is a concern that more serious eye diseases may be combined. For this reason, the establishment of a myopia progression prevention method for myopia in schoolchildhood with remarkable progression and myopia that develops after becoming an adult is expected (see Non-Patent Document 1).

  Myopia is broadly divided into two types: accommodative myopia and axial myopia. It is said that accommodative myopia involves adjustment by prolonged near work, that is, increase in lens refractive power due to increased contraction of ciliary muscle. Normally, when the near work is stopped, the ciliary muscle relaxes and the adjustment is released, but the state in which the contraction state in the long-term near work is fixed and myopia becomes apparent is referred to as adjustable myopia. On the other hand, in axial myopia, the eyeball length (the length from the cornea to the retina) is extended as the eyeball lengthens, and light rays from infinity are imaged in front of the retina. Intense myopia is said to be caused by an extension of the eye axis, and various experiments suggest that both the retina and the central nervous system are involved in the extension of the eye axis (see Non-Patent Document 1). However, the mechanism for developing myopia has not yet been elucidated.

  As an attempt to prevent the progression of myopia, pharmacotherapy is performed. For example, with regard to regulatory myopia, eyedrops of tropicamide (Midrin M®) have been tried as a method of improving the tension of the ciliary muscle relative to the mechanism of refractive myopia due to increased contraction of the ciliary muscle. It has been. However, the effect is not statistically significant (see Non-Patent Document 1).

  Atropine blocks its regulation by ciliary muscle relaxation, suppresses extension of axial length in animal experiments, inhibits eyeball growth of retinal cells by releasing dopamine, and grows from the pituitary gland that inhibits normal eyeball growth There is a report in Taiwan that it is thought that the myopia progression is suppressed by the action of suppressing the secretion of hormones, and the myopia progression was statistically significantly suppressed, but contact dermatitis, dawn by mydriasis, fog vision, Short-, medium- and long-term side effects such as the effect of ultraviolet rays on the retina and lens are problematic (see Non-Patent Document 1). Although pirenzepine prevented myopic blockade myopia by suppressing the extension of the axial length at the level of animal experiments (see Non-Patent Document 1), a 2-year clinical trial conducted in the United States for children aged 8-12 years However, a significant difference was observed for accommodative myopia (refraction of the lens), but no significant difference was observed for the axial length (see Non-Patent Document 2).

  A method of treating myopia by corneal refractive surgery that changes the refractive index of the cornea has also been performed. Although myopia is corrected by corneal refraction surgery, the axial axis itself remains unchanged, so axial myopia cannot be fundamentally treated, and the risk of surgery is high.

  Patent Document 1 discloses an ocular length control agent containing a transforming growth factor TGF-β modulator as an active ingredient. Patent Document 2 discloses general formula (I).

Wherein the ring A may be substituted, R ₁ represents hydrogen or an amino group which may be protected, and R ₂ represents a group capable of releasing a proton, or a salt thereof. Disclosed is a preventive or therapeutic agent for visual impairment. Patent Document 3 discloses an ophthalmic drug containing an effective amount of rispenzepine and nurezepine to prevent an abnormal increase in the axial length of an eye in an animal. However, these drugs have not yet reached clinical use.

  As described above, prevention with ophthalmic solutions has been attempted for control myopia, but for axial myopia, which is considered to be the cause of intense myopia, drugs that suppress the extension of the eye axis have been found at the level of animal experiments. There are no drugs that have been clinically proven to be effective in the prevention and treatment of axial myopia at this time. If it becomes possible to prevent and treat axial myopia, not only will it lead to an improvement in QOL, but it will also reduce the risk of developing the above serious eye diseases. Therefore, development of a clinically effective drug as a preventive or therapeutic agent for axial myopia is strongly desired.

Japanese Patent Laid-Open No. 9-301891 Japanese Patent Laid-Open No. 10-203982 JP-A-6-206820

Kenichi Yoshino, Myopia Treatment for School Children, “Treatment” August 2005 (Vol.87) Extra Special Issue, p1388-1392 Siatkowski RM, Cotter SA, Crockett RS, Miller JM, Novack GD, Zadnik K; US Pirenzepine Study Group. Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepineophthalmicgelinchildrenwithmyopia. In Press Corrected Proof, Available online 25 March 2008

  An object of the present invention is to provide a preventive or therapeutic agent for axial myopia that is excellent in preventing and treating axial myopia.

  As a result of intensive studies to solve the above-mentioned problems, the inventors of the present invention have found that when bradykinin having a vasodilating action is administered intravitreally in a chicken (chick) visual block myopia model, the length of the eye axis is prolonged. It was found to be significantly suppressed. The mechanism of the onset of axial myopia has not been elucidated so far, so there has been no effective prevention and treatment method for axial myopia. This finding indicates that vascular atrophy is involved in the lengthening of the axial length, that is, vascular atrophy is involved in the onset of axial myopia. This is the first time that it is extremely useful for the prevention and treatment of sexual myopia.

Furthermore, it is known that blood vessels are atrophied when myopia progresses to blindness (for example, Hiroko Ohno, Bulletin of Japanese Ophthalmology, Vol. 34, No. 6, 1244-1253, 1983). Since the preventive or therapeutic agent of the present invention contains a compound having a vasodilatory action as an active ingredient, it can prevent or treat not only the prevention and treatment of axial myopia but also the blindness due to the progression of axial myopia I came up with that. Based on this finding, the present inventors have made further studies to complete the present invention.
That is, the present invention relates to a preventive or therapeutic agent for axial myopia and includes the following inventions.

[1] A prophylactic or therapeutic agent for axial myopia comprising a compound having a vasodilating action as an active ingredient.
[2] The preventive or therapeutic agent for axial myopia according to [1], wherein the compound having a vasodilatory action is bradykinin.
[3] The preventive or therapeutic agent for axial myopia according to [1] or [2], which is for eye drop administration.
[4] The preventive or therapeutic agent for axial myopia according to the above [1] or [2], which is for intravitreal administration.
[5] The preventive or therapeutic agent for axial myopia according to the above [1] or [2], which is for oral administration.

  The present invention also provides a method for preventing or treating axial myopia, a compound having vasodilatory effect for preventing or treating axial myopia, and a method for administering axial myopia, wherein a compound having a vasodilatory effect is administered to an animal including a human. The use of a compound having a vasodilatory effect for the manufacture of a preventive or therapeutic agent.

  According to the present invention, it is possible to effectively suppress the extension of the axial length, and thus it is possible to prevent and treat axial myopia that has not been effective in preventing and treating so far.

The present invention is a prophylactic or therapeutic agent for axial myopia comprising a compound having a vasodilatory action as an active ingredient.
In the present invention, axial myopia is clear because the light passing through the cornea does not form an image on the retina, but forms an image in front of the retina due to the extension of the axial length (length from the cornea to the retina). It means myopia in a state where an image cannot be captured.

  In addition, in this specification, “treatment” refers to not only completely curing a disease state but also suppressing the progression and / or worsening of symptoms without complete cure, “Preventing” means preventing, suppressing, or delaying the onset of a disease state by improving a part or all of it and leading to the direction of healing.

  As the compound having a vasodilatory action used in the preventive or therapeutic agent for axial myopia of the present invention, for example, a vasodilatory peptide, a calcium channel inhibitor, an endothelin receptor antagonist, an angiotensin action inhibitor and the like are preferable.

  As the vasodilatory peptide, kinin is preferable. Kinin is a polypeptide produced by the degradation of plasma kininogen by the proteolytic enzyme kallikrein. As quinine, bradykinin, kallidin, lysyl bradykinin and the like are preferable. Of these, bradykinin is more preferable.

  Calcium channel inhibitors generally exhibit vasodilatory effects by suppressing Ca influx into cells, and are widely used for the treatment of various cardiovascular diseases. Examples of calcium channel inhibitors include benzodiazepine derivatives such as diltiazem hydrochloride; phenylalkylamine derivatives such as verapamil hydrochloride and bepridil hydrochloride; dihydropyridine derivatives such as nifedipine hydrochloride, nicardipine hydrochloride and nimodipine hydrochloride; piperazine derivatives such as cinnarizine and flunarizine; For example, fasudil.

  Examples of the endothelin receptor antagonist include bosentan. An angiotensin action inhibitor includes captopril and the like.

  The compound having a vasodilatory effect can be produced by a known method. Moreover, a commercial item can also be used. Of the compounds having a vasodilatory effect, for example, bosentan is commercially available from Acterion Pharmaceuticals, Inc. as TRAKRIA (registered trademark) tablets. Captopril is commercially available from Daiichi Sankyo Co., Ltd. as Captolyl (registered trademark) tablets. Bradykinin is commercially available from Wako Pure Chemical Industries under the trade name bradykinin.

  The agent for preventing or treating axial myopia of the present invention can be produced, for example, by mixing a compound having a vasodilatory effect and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers include solid preparations, excipients (eg, lactose, corn starch, mannitol, crystalline cellulose, soft anhydrous silicic acid, etc.), lubricants (eg, magnesium stearate, calcium stearate, talc, Polyethylene glycol, colloidal silica, etc.), binder (sucrose, mannitol, maltitol, starch, syrup, gum arabic, gelatin, tragacanth gum, sodium alginate, chitin, chitosan, polyvinylpyrrolidone, etc.), disintegrant (eg, potato starch, carboxy Methylcellulose calcium, croscarmellose sodium, chitin, chitosan, etc.) and in liquid preparations, water, alcohols such as non-aqueous vehicles (eg, ethanol, propylene glycol, glycerin; Oils such as buoy oil, almond oil, sesame oil, cottonseed oil, castor oil, corn oil; oily esters, etc., solubilizers (eg, polyvinylpyrrolidone, cyclodextrin, caffeine, polyethylene glycol, propylene glycol, mannitol, benzoic acid) Benzyl, trisaminomethane, cholesterol, etc.), suspending agents (for example, surfactants such as stearyltriethanolamine, sodium lauryl sulfate, polysorbate 80; hydrophilic polymers such as hydroxyethylcellulose, carboxymethylcellulose, gelatin, sorbit syrup) Etc.), thickeners (eg egg yolk lecithin, gelatin, gum arabic, tragacanth gum, methylcellulose, pectin etc.), tonicity agents (eg sorbitol, glycerin, polyethyleneglycol) , Glucose, sodium chloride, etc.), emulsifier (eg, lecithin, sorbitan monooleate, etc.), buffer (eg, phosphate buffer, borate buffer, citrate buffer, tartrate buffer, acetate buffer) Etc.), a soothing agent (for example, benzyl alcohol, etc.) and the like are appropriately blended. In addition, preservatives (eg, paraoxybenzoates, benzalkonium chloride, chlorobutanol, etc.), chelating agents (eg, sodium edetate, sodium citrate, condensed sodium phosphate, etc.), antioxidants as necessary (Eg, nitrite, ascorbic acid, cysteine, etc.), coloring agents (eg, tar pigments, licorice extract, riboflavin, etc.), sweeteners (glucose, sucrose, saccharin, etc.), flavoring agents (eg, vanillin, menthol, etc.) ), Fragrances (for example, fennel oil, menthol, etc.) may be added according to conventional methods. In addition to the above, agar, casein, collagen and the like are exemplified as pharmaceutically acceptable carriers.

  The agent for preventing or treating axial myopia of the present invention is administered orally or parenterally. Examples of the preparation for oral administration include solid preparations such as tablets, powders, granules and capsules; and liquid preparations such as emulsions, syrups and suspensions. Examples of the preparation for parenteral administration include injections, ointments, eye drops and the like. The agent for preventing or treating axial myopia of the present invention is preferably used in a form for local ocular administration from the viewpoint of effects. Examples of the preparation for topical ocular administration include eye drops, injections (intravitreal injections, subconjunctival injections, and tenon's injections), eye ointments, and ophthalmic gels. The agent for preventing or treating axial myopia of the present invention is preferably used in the form of eye drops or intravitreal injections when administered parenterally. These preparations are preferably used as sustained release agents. This is because the administration interval can be increased and the number of administrations can be reduced. In particular, since frequent injection into the local area of the eye increases the risk of complications, it is preferable to use a sustained-release agent in the injection. The sustained release agent can be produced by a known method. Specifically, for example, a sustained-release agent containing a drug in fine particles such as biodegradable polymers (such as polylactic acid), natural polymers (such as collagen and hyaluronic acid), and synthetic polymers (such as methacrylic acid copolymers). Is mentioned.

  Tablets are produced by appropriately adding the above-mentioned excipients, disintegrants, binders, lubricants and the like to the compound having a vasodilatory effect and compression molding. At this time, if desired, the above-mentioned sweetener, flavoring agent, fragrance and the like may be further added after compression molding, and coating may be performed by a method known per se in order to improve entericity or durability. Also good. Examples of the coating agent used for coating include hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, ethylcellulose, and cellulose acetate phthalate. The capsule may be a hard capsule or a soft capsule. A hard capsule can be usually produced by filling a capsule such as gelatin with a compound having a vasodilating action. A soft capsule can be usually produced by sandwiching a compound having a vasodilatory effect and a pharmaceutically acceptable carrier, if desired, in a sheet obtained by adding a plasticizer such as glycerin to gelatin, followed by pressure molding. The suspension can be produced, for example, by suspending a compound having a vasodilating action in the above-described solvent. At this time, the above-described suspending agent or the like may be appropriately used.

  Injections, for example, by dissolving a compound having a vasodilating action in water for injection together with the above-mentioned preservatives, isotonic agents, solubilizing agents, etc., or as aqueous injections, or propylene glycol, olive oil, sesame oil, cottonseed oil, etc. It can be produced as an oily injection by dissolving or suspending in a solution.

  Aqueous eye drops can be produced, for example, by heating purified water to dissolve the preservative, adding a solubilizing agent, and then adding a compound having a vasodilatory effect and completely dissolving. At this time, a buffer, an isotonic agent, a chelating agent, a thickener and the like may be used as necessary.

  The aqueous suspension ophthalmic solution can be produced by appropriately selecting and using the above-described suspending agent in addition to the additives used in the aqueous eye drop. The aqueous eye drop and the aqueous suspension eye drop are preferably used after being adjusted within the pH range usually used for eye drops, and usually about 4 to 9, preferably about 5 to 8.

  Non-aqueous eye drops are compounds having a vasodilatory action, such as water-soluble solvents such as alcohols (eg, ethanol, ethylene glycol, macrogol, propylene glycol, glycerin, etc.) and fats and oils (eg, olive oil, sesame oil, peanut oil, cottonseed oil, It can be produced by dissolving or suspending it in an oily solvent such as castor oil or corn oil.

  The eye ointment can be produced by appropriately selecting, for example, petrolatum, plastibase, liquid paraffin or the like as a base.

  The ophthalmic gel can be produced by appropriately selecting and using, for example, carboxyvinyl polymer, ethylene maleic anhydride polymer, polyoxyethylene-polyoxypropylene block copolymer, gellan rubber and the like as a base.

  The amount of the active ingredient in the agent for preventing or treating axial myopia of the present invention is not particularly limited as long as the active ingredient exerts a vasodilatory effect, but it is usually about 0.0001 to 100% by weight of the preparation. Yes, preferably about 0.001 to 50% by weight. The dose and frequency of administration vary depending on age, weight, dosage form, etc., but when used as eye drops for adults, the compound having a vasodilatory effect is usually about 0.0001 to 10 w / v%, preferably A preparation containing about 0.001 to 1 w / v% can be administered usually several times per day, preferably 1 to 6 times, usually 1 time, preferably 1 to 3 drops. When used, a preparation containing a compound having a vasodilatory effect is usually about 0.0001 to 10 w / w%, preferably about 0.001 to 1 w / w%, usually once every 4 to 8 weeks. In general, about 0.01 to 0.2 mL can be administered at one time. In the case of oral administration, the compound having a vasodilatory effect can be usually administered at about 0.05 to 2 mg, preferably about 0.5 to 1.5 mg per kg body weight per day. It is preferable to administer 1 to 3 times a day.

  As the administration target of the agent for preventing or treating axial myopia of the present invention, mammals such as humans, mice, rats, rabbits, dogs, cats, cows, monkeys, and pigs are preferable, and humans are more preferable. Moreover, as an administration subject, a mammal that has developed or is likely to develop axial myopia is preferable.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated concretely, this invention is not limited to these Examples at all.

Example 1: Axial length suppression test using a chicken myopia model (1) Chicken visual block myopia model A six-day-old chick (white legphone) was obtained, and one eye was shielded with a mask made using vinyl tape. did. Occlusion was always performed on the right eye and the left eye was used as a control. The chicks were raised under normal breeding conditions.

(2) Compound having vasodilatory effect As a compound having a vasodilatory effect, bradykinin (manufactured by Wako Pure Chemical Industries, Ltd.) which is a vasodilator was used. Bradykinin was prepared to 93.75 pmol using physiological saline. Saline was used as a control.

(3) Administration method Bradykinin was injected into the vitreous cavity once a week (every 7 days) into chicks that were guided myopia by shielding. Specifically, chicks were anesthetized with Ketalar (registered trademark) and Selactal (registered trademark), and then inserted 2 mm outward from the corneal ring using a syringe for insulin injection.
In the bradykinin administration group, a 93.75 pmol solution of bradykinin was injected into 50 μL of vitreous. Since the chick's eye volume is about 1 mL, the final intraocular concentration of bradykinin is about 4.69 pmol. In the control group of the bradykinin administration group, 50 μL of physiological saline was injected into the vitreous body.

(4) Measurement of eyeball Four weeks after induction of myopia, the chick was sacrificed, the eyeball was removed, and the size of the left and right eyeballs was measured with a caliper. The degree of axial myopia was evaluated by the length in the longitudinal direction of the eye axis (axial length) and the maximum diameter in the lateral direction (maximum lateral diameter). The left and right axial length difference and the maximum lateral diameter difference were calculated, and the difference was regarded as the degree of myopia, and the difference between the degree of myopia induction in the control group and the degree of myopia induction when the drug was injected was compared.

(5) Results Table 1 shows the results of the bradykinin administration group and the control group. As is apparent from Table 1, the bradykinin-administered group significantly decreased the axial length and maximum lateral diameter compared to the control group.

In the table, ^* and ^** mean a significant decrease compared to the control group (Unpaired t-test ^* is P <0.05, ^** is P <0.01).

  As described above, since a compound having a vasodilatory action significantly suppressed the progression of axial myopia in the chick model, it was clarified that a compound having a vasodilator action can prevent and inhibit the extension of the eye axis.

Example 2
The same experiment as in Example 1 is performed except that kalidin or lysyl bradykinin is used in place of bradykinin as a compound having a vasodilating action. In the kallidin or lysyl bradykinin administration group, the extension of the axial length and the maximum transverse diameter are significantly suppressed as compared with the control group.

Example 3
The same experiment as in Example 1 is performed except that diltiazem hydrochloride is used instead of bradykinin. In the diltiazem hydrochloride administration group, the extension of the axial length and the maximum transverse diameter are significantly suppressed as compared with the control group.

Example 4
The same experiment as in Example 1 is performed except that verapamil hydrochloride or bepridil hydrochloride is used instead of bradykinin. In the verapamil hydrochloride administration group and the bepridil hydrochloride administration group, the extension of the axial length and the maximum transverse diameter are significantly suppressed as compared with the control group.

Example 5
The same experiment as in Example 1 is performed except that nifedipine hydrochloride, nicardipine hydrochloride or nimodipine hydrochloride is used instead of bradykinin. In the nifedipine hydrochloride administration group, the nicardipine hydrochloride administration group, and the nimodipine hydrochloride administration group, the extension of the axial length and the maximum transverse diameter are significantly suppressed as compared with the control group.

Example 6
The same experiment as in Example 1 is performed except that cinnarizine or flunarizine is used instead of bradykinin. In the cinnarizine administration group and the flunarizine administration group, the extension of the axial length and the maximum transverse diameter are significantly suppressed as compared with the control group.

Example 7
The same experiment as in Example 1 is performed except that fasudil hydrochloride is used instead of bradykinin. In the fasudil hydrochloride administration group, the extension of the axial length and the maximum transverse diameter are significantly suppressed as compared with the control group.

Example 8
The same experiment as in Example 1 is performed except that bosentan is used instead of bradykinin. In the bosentan administration group, the extension of the axial length and the maximum transverse diameter are significantly suppressed as compared with the control group.

Example 9
The same experiment as in Example 1 is performed except that captopril is used instead of bradykinin. In the captopril-administered group, the extension of the axial length and the maximum lateral diameter are significantly suppressed as compared with the control group.

  From Examples 2 to 9, it is possible to prevent and suppress the extension of the eye axis by the compound having a vasodilatory effect.

Example 10: Preparation Example Formulation 1: Eye drops Bradykinin, sodium dihydrogen phosphate dihydrate and sodium chloride are dissolved in sterilized purified water, adjusted to pH 7 with sodium hydroxide, and then sterilized purified water. Eye drops of the following formulation were prepared with a total volume of 100 mL.
100mg of bradykinin in 100mL
・ Sodium dihydrogen phosphate ・ Dihydrate 0.1g
・ 0.9g sodium chloride
-Sodium hydroxide Appropriate amount-Sterilized purified water Appropriate amount An eye drop containing 10 mg or 500 mg of bradykinin in 100 mL can be prepared in the same manner as in Formulation Example 1 above.

Formulation 2: Injection The injection of the following formulation was prepared by dissolving bradykinin and sodium chloride in bacteria-purified water and making the total volume 100 mL with sterile purified water.
In 100 mL, bradykinin 1 mg
・ 0.9g sodium chloride
-Sterilized purified water Appropriate amount In the same manner as in Formulation Example 2 above, an injection containing 0.5 mg or 2 mg of bradykinin in 100 mL can be prepared.

Formulation 3: Internal preparation (Manufacture of capsules)
Bradykinin, microcrystalline cellulose, lactose and magnesium stearate were mixed in the purified bacteria water and filled into gelatin capsules to prepare capsules having the following formulation.
・ Brazikinin 1mg
・ Microcrystalline cellulose 10mg
・ Lactose 19mg
・ Magnesium stearate 1mg
Note that capsules containing 0.5 mg or 2 mg of bradykinin in one capsule can be prepared in the same manner as in Formulation Example 3 above.

Formulation 4: Internal use (Manufacture of tablets)
The following components were mixed by a conventional method and then tableted to obtain 1000 tablets each containing 0.5 mg of the active ingredient.
・ Brazikinin 5g
・ Carboxymethylcellulose calcium 20g
・ Magnesium stearate 10g
・ Microcrystalline cellulose 920g
In the same manner as in the above Formulation Example 4, tablets containing 1 mg or 2 mg of bradykinin in each tablet can be prepared.

Example 11: Production Example In each of the above formulations 1 to 4, by using each compound used in Examples 2 to 9 instead of bradykinin, an ophthalmic solution containing each compound having a vasodilatory effect, an injection, Internal preparations and tablets can be produced.

  The present invention is not limited to the above-described embodiments and examples, and various modifications are possible within the scope shown in the claims, and technical means disclosed in different embodiments are appropriately combined. The obtained embodiment is also included in the technical scope of the present invention. Moreover, all the academic literatures and patent literatures described in this specification are incorporated herein by reference.

  The prophylactic or therapeutic agent of the present invention can effectively prevent and treat axial myopia, and is effective in preventing retinal complications, blindness, etc. due to high myopia, and thus is useful in the medical field. .

Claims (5)

  A prophylactic or therapeutic agent for axial myopia comprising a compound having a vasodilating action as an active ingredient.   The agent for preventing or treating axial myopia according to claim 1, wherein the compound having a vasodilatory action is bradykinin.   The agent for preventing or treating axial myopia according to claim 1 or 2, which is for eye drop administration.   The agent for preventing or treating axial myopia according to claim 1 or 2, wherein the agent is for intravitreal administration.   The agent for preventing or treating axial myopia according to claim 1 or 2, which is for oral administration.